Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated poliomyelitis vaccine (Sabin strains)
- Development stage
- Unknown
- Lead developer
- Sinopharm
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Inactivated Poliomyelitis Vaccine Sabin Strains (sIPV) is a trivalent inactivated viral vaccine developed for the prevention of poliomyelitis. Unlike the conventional Salk-IPV, which is manufactured using neurovirulent wild-type polioviruses, sIPV is produced using attenuated Sabin oral polio vaccine (OPV) strains grown on Vero cells. This manufacturing process significantly enhances biosafety by reducing the risk of environmental reintroduction of wild-type viruses. The vaccine contains inactivated poliovirus types 1, 2, and 3, which stimulate the immune system to produce neutralizing antibodies against all three serotypes. Versions of the vaccine have been developed by the Chinese Academy of Medical Sciences, Sinovac Life Sciences, and Nanolek, with Sinovac's version receiving WHO prequalification in 2022 to support global polio eradication efforts.
- Brand names
- PoliovacSinEupolio
- Other names
- Sabin IPVinactivated poliovirus vaccine (Sabin strains)
Beyond the preview
Go deeper on inactivated poliomyelitis vaccine (Sabin strains).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated poliomyelitis vaccine (Sabin strains).